On March 5, 2024 Bonum Therapeutics, a biopharmaceutical company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, reported the first public presentation of preclinical data on its lead program, a conditionally active LAG3-IL2 therapeutic (Press release, Bonum Therapeutics, MAR 5, 2024, View Source [SID1234640836]). Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024, taking place April 5-10 in San Diego, CA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details are as follows:
Abstract Title: "A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 capable of delivering IL2 to LAG3+ cells while remaining inert on LAG3- cells."
Presenter: Justin Killebrew, PhD, Senior Director, Immuno-Oncology Discovery at Bonum Therapeutics
Abstract Number: 4062
Date/Time: Tuesday, April 9, 2024, 9:00 AM – 12:30 PM PT
Session Title: Immune Modulation with Cytokines
The poster presentation will highlight a conditionally active therapeutic called cLAG3-IL2 that targets IL-2 to LAG3+ cells while remaining systemically inert, even at high treatment doses. The in vivo safety and efficacy data described in the poster demonstrate that this program is suitable for progressing into the clinic.
John Mulligan, PhD, Bonum Therapeutics’ CEO, commented, "We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR (Free AACR Whitepaper)."
The poster will be available on the Bonum website on the day of the presentation.
Bonum is developing new therapies based on its proprietary platform of conditionally active therapeutics. The company is a spinout of Good Therapeutics, which developed the technology that Bonum is advancing. The merits of the platform were validated by the Roche acquisition of Good Therapeutics and its PD-1-regulated IL-2 program in September 2022.
Bonum’s core platform enables the engineering and development of a broad array of important medicines. Initially, Bonum is applying the technology to regulated cytokines, including IL-12, IFN-alpha, and TGF-beta for immuno-oncology applications. In parallel, it is seeking partners for applications of its technology in other disease areas where the partner brings expertise in a specific biology and can help guide choices to create new therapies and reach patients as quickly as possible.